Weight Loss

Ozempic vs Wegovy: Are They the Same Drug?

April 2026 · 5 min read

Ozempic and Wegovy are both semaglutide. Same molecule, same mechanism, same manufacturer. The confusion about how they're "different" is a regulatory artifact — one FDA approval for diabetes, another for weight management — combined with different dosing and different marketing.

Same drug, different approvals

Ozempic is FDA-approved to treat Type 2 diabetes and to reduce cardiovascular risk in patients with diabetes and heart disease. It's dosed at 0.25 mg, 0.5 mg, 1 mg, and 2 mg weekly.

Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It's dosed at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg weekly.

The molecule in the injection pen is the same. The differences are in dosing range (Wegovy goes higher), FDA labeling, and insurance coverage.

Why this matters in practice

Insurance coverage often hinges on labeled indication. A patient with diabetes gets covered for Ozempic but may not for Wegovy even though they're the same drug. A patient with obesity but not diabetes gets covered for Wegovy (if their plan covers weight-loss medications at all) but not Ozempic.

This creates a strange situation where physicians sometimes prescribe "off-label" uses — Ozempic for weight loss in a patient without diabetes, for example — to navigate cost and access issues. Clinically, the drug is identical. Administratively, the label matters enormously.

The weight loss trials

The major weight-loss clinical trial data for semaglutide was generated using 2.4 mg weekly — the top Wegovy dose. The STEP trials showed average weight reductions of around 15% of body weight over 68 weeks at this dose, compared with approximately 2-3% in the placebo group. Patients taking Ozempic at its top dose of 2 mg typically see somewhat smaller weight-loss effects, in part because the 2.4 mg dose is not available as Ozempic.

Why people think they're different drugs

Marketing. Different brand names, different packaging colors, different ad campaigns, different target audiences. The manufacturer (Novo Nordisk) has good business reasons to keep the two brands distinct even though the active ingredient is identical. Clinically, if a patient tolerates semaglutide well at 1 mg Ozempic, they will tolerate it similarly at 1 mg Wegovy.

What the shortage situation looked like

Semaglutide had significant supply shortages through much of 2023 and 2024, which drove a compounded-semaglutide market that has since contracted as branded supply stabilized. Compounded versions are generally being wound down as the FDA considers the shortages resolved. Patients on compounded formulations should plan to transition to branded products with their prescriber.

The takeaway

If a prescriber offers you "Ozempic" for weight management and you were expecting "Wegovy," don't panic — it's the same medication. The important questions are the dose, the titration schedule, and the source of the medication, not the brand name on the pen. For maximum weight-loss effect, the 2.4 mg dose (available under the Wegovy label) is where the trial data is strongest.

Ready to get real answers about your health?

Join the Waitlist — Get 50% Off